Immuneering (NASDAQ:IMRX - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.01), FiscalAI reports.
Immuneering Stock Performance
NASDAQ:IMRX traded down $0.04 during trading hours on Wednesday, reaching $4.36. The stock had a trading volume of 259,348 shares, compared to its average volume of 1,435,640. The stock has a 50 day simple moving average of $4.62 and a 200 day simple moving average of $4.99. The stock has a market cap of $281.77 million, a P/E ratio of -3.71 and a beta of 0.43. Immuneering has a 12-month low of $2.90 and a 12-month high of $10.08.
Institutional Trading of Immuneering
Several hedge funds and other institutional investors have recently bought and sold shares of IMRX. SummitTX Capital L.P. bought a new stake in shares of Immuneering in the 4th quarter worth approximately $69,000. Price T Rowe Associates Inc. MD grew its stake in shares of Immuneering by 10.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,993,958 shares of the company's stock valued at $13,121,000 after buying an additional 195,176 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of Immuneering in the fourth quarter worth about $607,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Immuneering in the 4th quarter valued at about $315,000. Finally, Landscape Capital Management L.L.C. bought a new position in Immuneering during the 4th quarter worth approximately $542,000. Hedge funds and other institutional investors own 67.65% of the company's stock.
Analysts Set New Price Targets
A number of research firms have issued reports on IMRX. Oppenheimer reiterated an "outperform" rating on shares of Immuneering in a research report on Monday, June 1st. Wall Street Zen downgraded shares of Immuneering from a "hold" rating to a "sell" rating in a research note on Monday, July 20th. Needham & Company LLC lifted their price target on shares of Immuneering from $11.00 to $18.00 and gave the company a "buy" rating in a report on Monday, July 20th. Chardan Capital reissued a "buy" rating and issued a $20.00 price objective on shares of Immuneering in a research note on Tuesday, May 19th. Finally, Cantor Fitzgerald assumed coverage on shares of Immuneering in a research report on Wednesday, July 8th. They issued an "overweight" rating and a $17.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Immuneering presently has an average rating of "Moderate Buy" and a consensus target price of $17.57.
View Our Latest Report on IMRX
About Immuneering
(
Get Free Report)
Immuneering Nasdaq: IMRX is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.
The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
